Vera Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 51
- Market Cap
- $2B
- Website
- http://www.veratx.com
- Introduction
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Clinical Trials
17
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Monthly Dosing of Atacicept in IgAN
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Vera Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT07020923
- Locations
- 🇺🇸
Vera Therapeutics, Brisbane, California, United States
Atacicept in Multiple Glomerular Diseases
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Vera Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06983028
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- Conditions
- IgA Nephropathy (IgAN)Renal and Urinary DisordersBerger Disease
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Vera Therapeutics, Inc.
- Target Recruit Count
- 476
- Registration Number
- NCT06674577
- Locations
- 🇺🇸
Vera Therapeutics, Brisbane, California, United States
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Vera Therapeutics, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT05609812
- Locations
- 🇺🇸
Vera Site # 0139, Huntsville, Alabama, United States
🇺🇸Vera Site # 0138, La Jolla, California, United States
🇺🇸Vera Site # 0127, La Palma, California, United States
Atacicept in Subjects With IgA Nephropathy
- Conditions
- IgA NephropathyBerger Disease
- Interventions
- Other: Placebo to match Atacicept
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Vera Therapeutics, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT04716231
- Locations
- 🇺🇸
ORIGIN 3 Global Site Contact Information, Brisbane, California, United States
- Prev
- 1
- 2
- Next